Medicilon Inc.’s Post

We're delighted to introduce one of our esteemed speakers for the ET Future-Ready Pharma Supply Chain Summit - Dr Rajiv Desai, Senior Technical Advisor at the Indian Pharmaceutical Alliance! Join us as Dr. Desai shares his extensive expertise and insights into advancing pharmaceutical supply chain technologies and practices. Don't miss out on this exclusive opportunity to learn from a prominent figure in the industry. Register Now: https://bitly.ws/34Mps #ETPharmaSupplyChainSummit #SupplyChainSummit #ETPharmaSupplyChain #PharmaSummit2023 #HealthcareInnovation #Mumbai #InnovationInSupplyChain

First Issue of 2024 - "FDA's What’s New in Regulatory Science" Published: 29 April 2024 This is a quarterly newsletter published by the Center for Drug Evaluation and Research (CDER) at the US Food and Drug Administration (#FDA). It highlights recent advancements, prospects, and efforts in drug development and regulatory science, aiming to promote progress in medical product development. For more information: https://lnkd.in/gictMhvH #FDA #pharma #pharmaceutical #regulatoryaffairs #whatisnew PharmOut #pharmout

🔈 🔉 🔊 We are excited to announce the upcoming panel discussion focusing on the relevance of sustainability in the pharmaceutical industry. Join us as we hear from pharmaceutical experts, including Hans Christian Eder from ZETA GmbH, as they share their insights and perspectives. Check out the event details here ▶ : https://lnkd.in/dnPjtNaA Be sure to mark your calendars and join us for this important conversation 👥. #paneldiscussion #sustainability #pharmaceuticalindustry

Early commercial engagement in the drug product lifecycle is becoming an increasingly important aspect of a successful, timely commercial launch.    By engaging the advice, expertise, and services of your chosen commercial CDMO partner early, ideally during Phase II to III, you ensure that processes involving long lead times are factored in, alongside adequate research into the drug delivery platforms and their specific technical requirements.   Read more from PCI Pharma Services’ Paul Smallman as he outlines with Pharmaceutical Technology, the industry trends in commercial packaging, offering key advice on maximizing the chances of success, and discusses real-world case studies based on front-line experience in this field.   https://lnkd.in/ephEqUvt   #CDMO #CommercialPackaging #PharmaOutsourcing   #LetsTalkFuture

Thank you, Mert Zorlular and Mihaela Vuksic, DBA, for writing this insightful and much-needed article that highlights critical aspects of early access to novel medicines—a topic that is often misunderstood. Some of the key points I would like to emphasize in the article include:   1️⃣ Access Works Differently Outside “Core” Markets: Market access strategies in many international markets do not function the same way as they do in the U.S. or Western Europe and require a different approach. 2️⃣ Early Access is, In Most Cases, is not Easy Access: In these markets, products may be reimbursed, sold and supplied on a Named Patient basis, often with requirements, which is unlike similar programs in the Western context. But these programs are not “backdoors” to otherwise difficult markets, they are often part of a holistic policy approach and require close collaboration with the local payers, regulators and medical community, along with extensive compliance requirements. 3️⃣ Different Partners for Different Goals: If the main goal is to deliver products free of charge on a compassionate use basis, or to send a limited number of packs reactively, there are many alternatives that offer these services on a fee basis. (These are not outlined in our article and not part of Er-Kim’s business model.) While traditional EAPs in Western markets are often outsourced to companies that deliver this service, our partners work directly with us and alternative partners who cover other parts of the world, following the approach we discuss in The Pharma Letter.   Understanding these nuances is crucial for pharmaceutical companies aiming to provide life-saving treatments to patients worldwide. By integrating EAPs and other non-traditional strategies into our business models, we can ensure timely access to medicines for those who need them most.

Despite its role in improving people’s lives, the pharmaceutical sector hasn’t always put the patient at the center of how it operates. From drug discovery through clinical trials to commercialization, this article explains why a patient centric approach is now vital: https://lnkd.in/gPH7S8iA #pharma #patientcentricity #innovation

The easiest way to test if a gastric protection and enteric release could boost the bioavailability of your drug: easy POC in rodents!

In the latest episode of #Biopharma R&D Practitioner Voices, Marc P. Philipp and Pia K. are joined by Michael May, medical director Germany at Bristol Myers Squibb, and Matthias Meergans, general manager for research and development at Verband Forschender Arzneimittelhersteller e.V. (VFA) Germany, to discuss the actions Germany can take to attract more #research and development in the #pharmaceutical industry. Watch the full interview here: https://bit.ly/3U3hA90

Pharmaceutical Industry Trends 2024: Strategic Implications The National Pharmaceutical Congress just released the latest edition of the NPC Healthbiz Weekly, outlining five key trends shaping the #lifesciences sector this year. For #pharma managers, executives and decision-makers, this analysis offers: • A ranking of the most influential factors in the current landscape • Insights into the evolving pharmaceutical environment • Potential influences on strategic planning and operations How are we, as industry #leaders, adapting to these metamorphoses? We welcome your perspectives on which trends may significantly affect your organization. Check out this week's issue at https://lnkd.in/gxcsVRQ3 NPC Healthbiz Weekly is created by Chronicle Companies with support from Impres. Subscribe at https://lnkd.in/egugfuE and never miss an issue.

The topic of early access programs and how this strategy can be implemented prior to the broader commercialization of medicines is an important one that was covered in The Pharma Letter’s Expert View, by Er-Kim’s Mert Zorlular and Mihaela Vuksic, DBA. By integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies. Read the full article here: https://lnkd.in/e-_tCSRS